Analysts at StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a note issued to investors on Monday. The firm set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
Shares of PULM stock opened at $2.15 on Monday. The firm has a market capitalization of $7.85 million, a price-to-earnings ratio of -0.89 and a beta of 0.99. The company has a 50 day moving average price of $1.99 and a 200 day moving average price of $1.90. Pulmatrix has a one year low of $1.55 and a one year high of $2.73.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its earnings results on Friday, May 10th. The biotechnology company reported $0.23 earnings per share for the quarter. Pulmatrix had a negative return on equity of 44.05% and a negative net margin of 75.73%. The business had revenue of $5.89 million for the quarter.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
See Also
- Five stocks we like better than Pulmatrix
- Stock Market Upgrades: What Are They?
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Profitably Trade Stocks at 52-Week Highs
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
